OncoCyte (LTS:0KCC) Accounts Payable & Accrued Expense : $2.77 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Accounts Payable & Accrued Expense?

OncoCyte's quarterly accounts payable & accrued expense declined from Sep. 2023 ($3.19 Mil) to Dec. 2023 ($2.52 Mil) but then increased from Dec. 2023 ($2.52 Mil) to Mar. 2024 ($2.77 Mil).

OncoCyte's annual accounts payable & accrued expense declined from Dec. 2021 ($5.28 Mil) to Dec. 2022 ($5.20 Mil) and declined from Dec. 2022 ($5.20 Mil) to Dec. 2023 ($2.52 Mil).

OncoCyte Accounts Payable & Accrued Expense Historical Data

The historical data trend for OncoCyte's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Accounts Payable & Accrued Expense Chart

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.80

2.72

5.28

5.20

2.52

OncoCyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															3.88	3.18	3.19	2.52	2.77

OncoCyte Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

OncoCyte (LTS:0KCC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (LTS:0KCC) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

OCX:USA

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (LTS:0KCC) Headlines

No Headlines